Company Filing History:
Years Active: 2025
Title: Janet Leeds: Innovator in Hematologic Cancer Treatment
Introduction
Janet Leeds is a prominent inventor based in South San Francisco, CA (US). She has made significant contributions to the field of hematologic cancer treatment through her innovative research and development efforts. Her work focuses on addressing the challenges faced by patients with B-cell malignancies.
Latest Patents
Janet Leeds holds a patent for Cerdulatinib, which is designed for the treatment of B-cell malignancies. The patent outlines compositions and methods for treating relapsed or refractory hematologic cancer in human patients. The methods involve administering a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof. This treatment is particularly beneficial for patients suffering from chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), or other transformed FL, especially those who have relapsed or not responded to prior chemotherapy.
Career Highlights
Janet Leeds is associated with Alexion Pharmaceuticals, Inc., where she continues to advance her research in cancer therapies. Her dedication to improving patient outcomes is evident in her innovative approaches to treatment.
Collaborations
Some of her notable coworkers include Anjali Pandey and Gregory Coffey, who contribute to the collaborative efforts in research and development at Alexion Pharmaceuticals.
Conclusion
Janet Leeds is a key figure in the fight against hematologic cancers, with her patent for Cerdulatinib representing a significant advancement in treatment options. Her work exemplifies the impact of innovation in the medical field, particularly in addressing the needs of patients with challenging conditions.